期刊文献+

维持性血液透析患者甲状旁腺体积增大的相关性研究 被引量:6

The Association of Parathyroid Gland Enlargement and Risk Factors in Patients with Maintenance Hemodialysis
下载PDF
导出
摘要 目的探讨维持性血液透析患者甲状旁腺体积增大的发生率及其相关因素。方法176例维持性血液透析患者,用彩色多普勒测量其甲状旁腺体积,并同时检测患者血清全段甲状旁腺激素(intact parathyroid hormone,iPTH)、血钙、血磷、血清碱性磷酸酶(alkaline phosphatase,AKP)等骨代谢指标。结果1)根据血清iPTH结果176例维持性血液透析患者分为高iPTH组(血清iPTH>300ng/L)84例(47.7%),正常iPTH组(血清iPTH150~300ng/L)32例(18.2%),低iPTH组(血清iPTH<150ng/L)60例(34.1%)。2)176例维持性血液透析患者中有60例伴有甲状旁腺体积增大(34.1%),其中高iPTH组有48例(57.1%)、正常iPTH组4例(12.5%)、低iPTH组8例(13.3%)。高iPTH组患者甲状旁腺体积增大的发生率明显高于正常iPTH组和低iPTH组(P<0.05)。高PTH组甲状旁腺体积增大的程度亦明显高于正常PTH组和低PTH组(P<0.05)。3)甲状旁腺体积增大与透析龄≥5年、不规律服用活性维生素D3制剂的比例、血磷和血碱性磷酸酶水平呈正相关,与血液滤过次数<2次/月和血钙水平呈负相关。结论维持性血液透析患者甲状旁腺体积增大的发生率较高,多发生于甲状旁腺激素高分泌组。透析龄、不规律服用活性维生素D3制剂、血iPTH是甲状旁腺体积增大的独立危险因素。 Objective To investigate the incidence and risk factors of parathyroid gland enlargement in patients on maintenance hemodialysis.Methods A total of one hundred and seventy-six cases with uremia on maintenance hemodialysis were studied in terms of parathyroid gland size and bone metabolism index,such as serum intact parathyroid hormone(iPTH),calcium,phosphorus and alkaline phosphatase(ALP) etc.Results 1) According to the result of serum iPTH,176 patients with uremia on maintenance hemodialysis were divided i...
作者 王世相 李寒
出处 《首都医科大学学报》 CAS 2008年第3期369-372,共4页 Journal of Capital Medical University
关键词 血液透析 甲状旁腺激素 甲状旁腺体积 hemodialysis parathyroid hormone parathyroid gland enlargement
  • 相关文献

参考文献10

  • 1[1]Silver J,Kilav R,Naveh-Many T.Mechanisms of secondary hyperparathyroidism[J].Am J Physiol Renal Physiol,2002,283:F367-F376. 被引量:1
  • 2[2]McCarron D A,Muther R S,Lenfesty B,et al.Parathyroid function in persistent hyperparathyroidism:relationship to gland size[J].Kidney Int,2002,22:662-670. 被引量:1
  • 3[3]Fukagawa M,Kitaoka M,Yi H,et al.Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitrio l pulse therapy in chronic dialysis patients[J].Nephron,2004,68:221-228. 被引量:1
  • 4[4]McCarron D A,Muther R S,Lenfesty B,et al.Parathyroid function in persistent hyperparathyroidism:relationship to gland size[J].Kidney Int,2002,22:662-670. 被引量:1
  • 5[5]Wada M,Nagano N.Control of parathyroid cell growth by calcimimetics[J].Nephrol Dial Transplant,2003,(Suppl 3):12-16. 被引量:1
  • 6[6]Goodman W G.Recent developments in the management of secondary hyperparathyroidism[J].Kidney Int,2001,59:1187-1201. 被引量:1
  • 7[7]Aucella F,Morrone L,Stallone C,et al.The genetic background of uremic secondary hyperparathyroidism[J].J Nephrol,2005,18:537-547. 被引量:1
  • 8[8]Katoh N,Nakayama M,Shigematsu T,et al.Presence of sonographically detectable parathyroid glands can predict resistance to oral pulse-dose calcitriol treatment of secondary hyperparathyroidism[J].Am J Kidney Dis,2000,35:465-468. 被引量:1
  • 9[9]Nakamura M,Fuchinoue S,Teraoka S.Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism[J].Am J Kidney Dis,2003,42:739-745. 被引量:1
  • 10[10]Francesco L,Jorge-B C A,Tilman B D,et al.Management of disturbance of calcium and phosphate metabolism in chronic renal insufficiency with emphasis on the control of hyperphosphataemi[J].Nephrol Dial Transp lant,2002,17:723-731. 被引量:1

同被引文献46

引证文献6

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部